Study of the Combination of CM082 With Everolimus in Patients With mRCC
Status:
Unknown status
Trial end date:
2018-06-01
Target enrollment:
Participant gender:
Summary
This is a Phase I Dose-Escalation Study to Evaluate the Safety, Tolerability,
Pharmacokinetics, and Preliminary Efficacy of CM082 in Combination with Everolimus in Chinese
Patients With Advanced Renal Cell Carcinoma.